Form 4: Neurocrine Biosciences Executive Exercises Stock Options

Julie Cooke, Chief Human Resources Officer at Neurocrine Biosciences, exercised stock options for 6,468 shares of common stock at a price of $61.82 on May 16, 2025.

Summary

• On May 16, 2025, Julie Cooke, the Chief Human Resources Officer of Neurocrine Biosciences, exercised stock options to acquire 6,468 shares of common stock.
• The exercise price was $61.82 per share.
• Following the transaction, Ms. Cooke directly owns 26,858 shares of Neurocrine Biosciences common stock.
• 24,994 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.
• Includes an aggregate of 200 shares purchased on February 28, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
• The exercised options were part of an incentive stock option plan, with the options expiring on October 2, 2027.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing a routine stock option exercise. It doesn't inherently convey positive or negative sentiment.

Industry Context

Executive stock option exercises are a common practice in publicly traded companies, aligning executive interests with shareholder value. This filing is a routine disclosure required by the SEC.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it slightly increases the number of outstanding shares.

Key Dates

Keywords

stock options, Neurocrine Biosciences, NBIX, executive compensation, Form 4, insider trading, Julie Cooke, Chief Human Resources Officer